Pipeline

Pentixapharm develops innovative diagnostic and therapeutic compounds targeting hemato-oncology, adrenal disorders, and solid tumors. The leading candidate, PentixaFor, is advancing in a Phase III study for marginal zone lymphoma (Europe) and is preparing for another Phase III study in primary aldosteronism (USA). PentixaTher is in clinical trials for various blood cancers and solid tumors. Beyond its CXCR4-focused drug candidates, Pentixapharm has expanded its portfolio with radionuclide-antibody conjugates from Glycotope.

CXCR4 as target molecule

Our target protein is the G-protein-coupled receptor C-X-C motif chemokine receptor 4 (CXCR4). This receptor is involved in the regulation of a variety of processes such as the regulation of blood formation (haematopoiesis), the movement of stem cells (migration) and the formation of new blood vessels (angiogenesis). These processes take place in a healthy body, but if they degenerate, they contribute to the supply of oxygen and nutrients to tumors.

An increased occurrence of CXCR4 has been observed in benign tumors of the adrenal gland and in over 20 malignant cancers, in which the receptor is associated with tumor growth, metastasis and resistance to therapy. The receptor is therefore a suitable target molecule for the precise detection of tumors and their treatment.

Established and validated mode of action

A radioactive isotope (payload) is conjugated to a biologically active molecule, known as a ligand. This compound is then administered into the bloodstream via intravenous injection and will navigate to all the affected cells in the body, including small metastases. The choice of radioisotope determines the outcome: High-energy isotopes are used to kill the targeted cells, while low-energy isotopes are used for imaging.

Literature

CXCR4 is one of the most thoroughly researched targets of the last decade:

  • 9 Reviews, 2 method articles, >100 Publications on [68Ga]Ga-PentixaFor

  • More than 2,500 Patients have already been imaged with [68Ga]Ga-PentixaFor without any safety issues

  • Since 2024, 474 patients were diagnosed for PA with [68Ga]Ga-PentixaFor

To support academic research, PTX sponsors more than 20 investigator initiated clinical studies (IIS). You can find an overview of the most important publications, listed by topic and area, here.